Diltiazem, a L-type Ca(2+) channel blocker, also acts as a pharmacological chaperone in Gaucher patient cells.
about
An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants)New therapeutic approaches for Krabbe disease: The potential of pharmacological chaperonesIn vivo and ex vivo evaluation of L-type calcium channel blockers on acid beta-glucosidase in Gaucher disease mouse modelsIdentification and characterization of ambroxol as an enzyme enhancement agent for Gaucher diseaseEvaluation of N-nonyl-deoxygalactonojirimycin as a pharmacological chaperone for human GM1 gangliosidosis leads to identification of a feline model suitable for testing enzyme enhancement therapy.Aberrant Ca2+ handling in lysosomal storage disordersDrug repositioning for enzyme modulator based on human metabolite-likeness.The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase.Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders.Adamantyl glycosphingolipids provide a new approach to the selective regulation of cellular glycosphingolipid metabolism.Disease-drug pairs revealed by computational genomic connectivity mapping on GBA1 deficient, Gaucher disease mice.Review of the safety and efficacy of imiglucerase treatment of Gaucher disease.Animal models for Gaucher disease research.Induced Pluripotent Stem Cell Modeling of Gaucher's Disease: What Have We Learned?Modulating ryanodine receptors with dantrolene attenuates neuronopathic phenotype in Gaucher disease mice.Neuroprotective properties of mildronate, a small molecule, in a rat model of Parkinson's disease.Connecting Ca2+ and lysosomes to Parkinson disease.Drug repositioning can accelerate discovery of pharmacological chaperones.Optimal therapy in Gaucher diseaseAmbroxol as a pharmacological chaperone for mutant glucocerebrosidase.
P2860
Q24601525-FE852472-884A-456A-BF48-4FABD1EC6F73Q28068142-ADE21BAB-EA75-40A3-906F-3DDB816F1611Q28476287-7AFC6105-C083-4140-8942-5FBC23B734D2Q33478327-4F5D40A4-55B9-44BC-90B5-5114EF11B52FQ33568024-B58AB2B5-89C9-473C-A553-A5F16E8A85CEQ33727058-5221183F-AB26-4EB7-AE50-5A5039098798Q33802239-976C3AB8-E472-4E6B-ADC8-EE9847CC1560Q33870303-8B028B98-2641-4A41-B9DE-A6A32880AE7DQ35007910-BB70884F-66A1-4FEC-A0E2-2549A60A1E17Q35065197-45A4966F-7B1C-4B48-A6CD-EE38F3D0540AQ36040753-19C05CC4-BFA8-4F7E-9C98-76A166135F96Q37354438-4FFD7ECD-29F6-443B-8D97-51684C35CFDCQ37939781-85EA0094-5AD9-41B2-998F-24B4A020BDA2Q39254537-02B6BE14-8AD0-414B-8ACC-FE0F34312692Q39364713-8EA490FB-8100-46D2-AABE-3C92FB5052A8Q41106663-2C3EABA0-8917-4A62-806F-22FBB8722172Q42255446-CE5941D6-0E7C-45AA-9797-37403B814F8DQ42558415-E9014FA5-3DEC-4969-9F9F-35564546A0CEQ42705042-98C61F33-8EB5-410B-9DF1-861CF97BE53BQ42763507-E96DE7EA-0C13-49B2-AE2D-A17A64C5D276
P2860
Diltiazem, a L-type Ca(2+) channel blocker, also acts as a pharmacological chaperone in Gaucher patient cells.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Diltiazem, a L-type Ca(2+) cha ...... rone in Gaucher patient cells.
@en
Diltiazem, a L-type Ca(2+) cha ...... rone in Gaucher patient cells.
@nl
type
label
Diltiazem, a L-type Ca(2+) cha ...... rone in Gaucher patient cells.
@en
Diltiazem, a L-type Ca(2+) cha ...... rone in Gaucher patient cells.
@nl
prefLabel
Diltiazem, a L-type Ca(2+) cha ...... rone in Gaucher patient cells.
@en
Diltiazem, a L-type Ca(2+) cha ...... rone in Gaucher patient cells.
@nl
P2860
P921
P1476
Diltiazem, a L-type Ca(2+) cha ...... rone in Gaucher patient cells.
@en
P2093
Brigitte Rigat
Don Mahuran
P2860
P304
P356
10.1016/J.YMGME.2008.12.008
P577
2009-01-22T00:00:00Z